A first Phase I trial (AUGMENT-101) assessed the oral single-agent revumenib (SNDX-5613, a close homolog to VTP50469) in heavily pretreated patients (n = 68) with relapsed or refractory KMT2A-rearranged or NPM1-mutated AML [44]. This evidence concerns the gene KMT2A and acute myeloid leukemia.